Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


The MAP 2022 programme is now online

Access the online programme

The Molecular Analysis for Precision Oncology Congress 2022 will take place in Amsterdam, Netherlands, from 14 to 16 October.

MAP is the leading global meeting dedicated to precision oncology, defined as molecular profiling of tumours to identify targetable alterations. This oncology field is fast evolving and has now entered the mainstream of clinical practice.

By attending the Molecular Analysis for Precision Oncology Congress 2022, participants will gain deeper insights into precision medicine, cancer-stromal interactions, clonal evolution, metastatic dissemination and drug response and resistance.

Learning objectives

  • Provide up to date information on the molecular characterization and clonal evolution of solid tumours on different cancer populations
  • Understand emerging technologies for cancer profiling, including artificial intelligence and data analysis
  • Acquire a better understanding of mechanisms driving tumour expansion, metastatic dissemination and cross talk between malignancy, microenvironment and host
  • Learn about new targets (tumor microenvironment, (epi)genetic, novel immunotherapies, metabolism regulators) and new resistance to cancer therapies


ESMO-MORA: The Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.


All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).

The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.

The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.


The Congress webcasts will be available for all delegates and will include all the sessions of the official programme where speaker permission is granted. Once the virtual platform is closed, the on-demand content will be transferred to OncologyPRO and will be accessible to all registered delegates, non-Members for 24 months. ESMO Members who do not register for the Congress will have access to the resources 3 months after the end of the Congress.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.